Construction by Artificial Intelligence and Immunovalidation of Hypoallergenic Mite Allergen Der F 36 Vaccine

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Apr 11

PMID 38601166

Authors

Qiao-Zhi Qin

Jian Tang

Cai-Yun Wang

Zhi-Qiang Xu

Man Tian

Affiliations

Soon will be listed here.

Abstract

Background: The house dust mite (HDM) is widely recognized as the most prevalent allergen in allergic diseases. Allergen-specific immunotherapy (AIT) has been successfully implemented in clinical treatment for HDM. Hypoallergenic B-cell epitope-based vaccine designed by artificial intelligence (AI) represents a significant progression of recombinant hypoallergenic allergen derivatives.

Method: The three-dimensional protein structure of Der f 36 was constructed using Alphafold2. AI-based tools were employed to predict B-cell epitopes, which were subsequently verified through IgE-reaction testing. Hypoallergenic Der f 36 was then synthesized, expressed, and purified. The reduced allergenicity was assessed by enzyme-linked immunosorbent assay (ELISA), immunoblotting, and basophil activation test. T-cell response to hypoallergenic Der f 36 and Der f 36 was evaluated based on cytokine expression in the peripheral blood mononuclear cells (PBMCs) of patients. The immunogenicity was evaluated and compared through rabbit immunization with hypoallergenic Der f 36 and Der f 36, respectively. The inhibitory effect of the blocking IgG antibody on the specific IgE-binding activity and basophil activation of Der f 36 allergen was also examined.

Results: The final selected non-allergic B-cell epitopes were 25-48, 57-67, 107-112, 142-151, and 176-184. Hypoallergenic Der f 36 showed significant reduction in IgE-binding activity. The competitive inhibition of IgE-binding to Der f 36 was investigated using the hypoallergenic Der f 36, and only 20% inhibition could be achieved, which is greatly reduced when compared with inhibition by Der f 36 (98%). The hypoallergenic Der f 36 exhibited a low basophil-stimulating ratio similar to that of the negative control, and it could induce an increasing level of IFN-γ but not Th2 cytokines IL-5 and IL-13 in PBMCs. The vaccine-specific rabbit blocking IgG antibodies could inhibit the patients' IgE binding and basophil stimulation activity of Derf 36.

Conclusion: This study represents the first application of an AI strategy to facilitate the development of a B-cell epitope-based hypoallergenic Der f 36 vaccine, which may become a promising immunotherapy for HDM-allergic patients due to its reduced allergenicity and its high immunogenicity in inducing blocking of IgG.

References

Banerjee S, Weber M, Blatt K, Swoboda I, Focke-Tejkl M, Valent P . Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol. 2014; 192(10):4867-75. PMC: 4582415. DOI: 10.4049/jimmunol.1400064. View

Tulaeva I, Kratzer B, Campana R, Curin M, van Hage M, Karsonova A . Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?. Front Immunol. 2020; 11:1368. PMC: 7358538. DOI: 10.3389/fimmu.2020.01368. View

Durham S, Shamji M . Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2022; 23(5):317-328. PMC: 9575636. DOI: 10.1038/s41577-022-00786-1. View

Chen H, Li J, Cheng L, Gao Z, Lin X, Zhu R . China Consensus Document on Allergy Diagnostics. Allergy Asthma Immunol Res. 2021; 13(2):177-205. PMC: 7840865. DOI: 10.4168/aair.2021.13.2.177. View

Bublin M, Kostadinova M, Radauer C, Varga E, Hafner C, Schmidthaler K . Engineering of structural variants of the major peanut allergens Ara h 2 and Ara h 6 for allergen-specific immunotherapy. J Allergy Clin Immunol. 2018; 143(3):1226-1229.e10. DOI: 10.1016/j.jaci.2018.10.039. View

Sanchez-Trincado J, Gomez-Perosanz M, Reche P . Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. 2018; 2017:2680160. PMC: 5763123. DOI: 10.1155/2017/2680160. View

Dai L, Liu J, Zhao Q, Li M, Zhou Y, Chen Z . Investigation of Allergic Sensitizations in Children With Allergic Rhinitis and/or Asthma. Front Pediatr. 2022; 10:842293. PMC: 8964996. DOI: 10.3389/fped.2022.842293. View

Valenta R, Duchene M, Vrtala S, Birkner T, Ebner C, Hirschwehr R . Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. J Allergy Clin Immunol. 1991; 88(6):889-94. DOI: 10.1016/0091-6749(91)90245-j. View

Wambre E, James E, Kwok W . Characterization of CD4+ T cell subsets in allergy. Curr Opin Immunol. 2012; 24(6):700-6. PMC: 3729480. DOI: 10.1016/j.coi.2012.07.009. View

10.

Jiao Y, Song L, Xu Z, Zhu D, Yang Y, Tian M . Purification and characterization of enolase as a novel allergen in Platanus acerifolia pollen. Int Immunopharmacol. 2022; 113(Pt A):109313. DOI: 10.1016/j.intimp.2022.109313. View

11.

Cramer P . AlphaFold2 and the future of structural biology. Nat Struct Mol Biol. 2021; 28(9):704-705. DOI: 10.1038/s41594-021-00650-1. View

12.

Cirkovic Velickovic T, Thunberg S, Polovic N, Neimert-Andersson T, Gronlund H, van Hage M . Low levels of endotoxin enhance allergen-stimulated proliferation and reduce the threshold for activation in human peripheral blood cells. Int Arch Allergy Immunol. 2007; 146(1):1-10. DOI: 10.1159/000112497. View

13.

Coomes S, Kannan Y, Pelly V, Entwistle L, Guidi R, Perez-Lloret J . CD4 Th2 cells are directly regulated by IL-10 during allergic airway inflammation. Mucosal Immunol. 2016; 10(1):150-161. DOI: 10.1038/mi.2016.47. View

14.

Weber M, Niespodziana K, Linhart B, Neubauer A, Huber H, Henning R . Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. J Allergy Clin Immunol. 2017; 140(5):1433-1436.e6. PMC: 6392172. DOI: 10.1016/j.jaci.2017.03.048. View

15.

Mak K, Pichika M . Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2018; 24(3):773-780. DOI: 10.1016/j.drudis.2018.11.014. View

16.

Rauber M, Mobs C, Campana R, Henning R, Schulze-Dasbeck M, Greene B . Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells. Allergy. 2019; 75(2):450-453. DOI: 10.1111/all.13996. View

17.

Chen K, Focke-Tejkl M, Blatt K, Kneidinger M, Gieras A, DallAntonia F . Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. Allergy. 2012; 67(5):609-21. PMC: 4594777. DOI: 10.1111/j.1398-9995.2012.02794.x. View

18.

Paul S, Sidney J, Sette A, Peters B . TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates. Curr Protoc Immunol. 2016; 114:18.19.1-18.19.24. PMC: 4981331. DOI: 10.1002/cpim.12. View

19.

Bordas-Le Floch V, Le Mignon M, Bussieres L, Jain K, Martelet A, Baron-Bodo V . A combined transcriptome and proteome analysis extends the allergome of house dust mite Dermatophagoides species. PLoS One. 2017; 12(10):e0185830. PMC: 5628879. DOI: 10.1371/journal.pone.0185830. View

20.

Jutel M, Kosowska A, Smolinska S . Allergen Immunotherapy: Past, Present, and Future. Allergy Asthma Immunol Res. 2016; 8(3):191-7. PMC: 4773206. DOI: 10.4168/aair.2016.8.3.191. View